Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Eligible age
18–75 yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Efficacy in participants with type 2 diabetes mellitus will be evaluated. Safety and tolerability and other weight-related outcomes will be evaluated in both types of participants.
Sponsor: Kailera
Where it's recruiting
Chandler · Phoenix
Irvine · Lincoln · Northridge
Hamden
Jacksonville · Jupiter · Palm Springs · Pembroke Pines
Decatur
Chicago · Skokie
South Bend
Kenner
Garden City
Jefferson City · Kansas City
Spartanburg
Knoxville
Source: ClinicalTrials.gov · NCT07497880 · last updated 2026-07-28